Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 345

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update

Open access
Bex, Axel, Ghanem, Yasmin Abu, Albiges, Laurence, Bonn, Stephanie, Campi, Riccardo, Capitanio, Umberto, Dabestani, Saeed, Hora, Milan, Klatte, Tobias, Kuusk, Teele, Lund, Lars, Marconi, Lorenzo, Palumbo, Carlotta, Pignot, Geraldine, Powles, Thomas, Schouten, Natasha, Tran, Maxine, Volpe, Alessandro, Bedke, Jens·2025·European Urology

Abstract

BACKGROUND AND OBJECTIVE: The European Association of Urology (EAU) renal cell carcinoma (RCC) guideline panel has updated their evidence-based guidelines and recommendations for the management of RCC. Here we present a summary of the 2025 RCC guidelines updated with standardised methodology to provide reproducible evidence for the management of RCC. METHODS: For the 2025 update, a literature search was performed covering the period from May 1, 2023 to May 1, 2024 using the Medline, EMBASE, and Cochrane Libraries. The data search focused on meta-analyses, systematic reviews, randomised controlled trials (RCTs), and retrospective or controlled comparator-arm studies. Evidence was synthesised as outlined for all EAU guidelines. KEY FINDINGS AND LIMITATIONS: Clinical practise recommendations were updated in all chapters of the RCC guidelines on the basis of a structured literature search. The studies included were predominantly retrospective with matched or unmatched cohorts based on single- or multi-institutional data. Several prospective studies and RCTs provided data that resulted in recommendations based on higher levels of evidence. Specifically, updates include new recommendations on stereotactic body radiotherapy for localised RCC, adjuvant therapy, systemic therapy for clear-cell RCC in later lines, other subtypes, and a new chapter on hereditary RCC. CONCLUSIONS AND CLINICAL IMPLICATIONS: The 2025 RCC guidelines have been updated by a multidisciplinary panel of experts using methodological standards to provide a contemporary evidence base for the management of RCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2025.02.020

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 77 references

Research works printed but not linked: 55

  1. Mickisch, 2001, Guidelines on renal cell cancer, Eur Urol, 40, 252, 10.1159/000049783 · doi:10.1159/000049783
  2. Thorstenson, 2014, Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005–2010: a population-based study from the national Swedish kidney cancer register, Scand J Urol, 48, 231, 10.3109/21681805.2013.864698 · doi:10.3109/21681805.2013.864698
  3. Alcala, 2022, The relationship between blood pressure and risk of renal cell carcinoma, Int J Epidemiol, 51, 1317
  4. Gansler, 2020, Prevalence of cigarette smoking among patients with different histologic types of kidney cancer, Cancer Epidemiol Biomarkers Prev, 29, 1406, 10.1158/1055-9965.EPI-20-0015 · doi:10.1158/1055-9965.epi-20-0015
  5. Sun, 2021, Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: results from Canadian Kidney Cancer information system, Can Urol Assoc J, 15, 132
  6. Sand, 2013, Incidentally detected renal cell carcinomas are highly associated with comorbidity and mortality unrelated to renal cell carcinoma, Scand J Urol, 47, 462, 10.3109/21681805.2013.777364 · doi:10.3109/21681805.2013.777364
  7. Voss, 2020, Chest computed tomography for staging renal tumours: validation and simplification of a risk prediction model from a large contemporary retrospective cohort, BJU Int, 125, 561, 10.1111/bju.15001 · doi:10.1111/bju.15001
  8. Leveridge, 2011, Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy, Eur Urol, 60, 578, 10.1016/j.eururo.2011.06.021 · doi:10.1016/j.eururo.2011.06.021
  9. Hora, 2023, European Association of Urology Guidelines Panel on Renal Cell Carcinoma update on the new World Health Organization classification of kidney tumours 2022: the urologist’s point of view, Eur Urol, 83, 97, 10.1016/j.eururo.2022.11.001 · doi:10.1016/j.eururo.2022.11.001
  10. Capitanio, 2023, A renewal of the TNM staging system for patients with renal cancer to comply with current decision-making: proposal from the European Association of Urology guidelines panel, Eur Urol, 83, 3, 10.1016/j.eururo.2022.09.026 · doi:10.1016/j.eururo.2022.09.026
  11. Spaliviero, 2016, An arterial based complexity (ABC) scoring system to assess the morbidity profile of partial nephrectomy, Eur Urol, 69, 72, 10.1016/j.eururo.2015.08.008 · doi:10.1016/j.eururo.2015.08.008
  12. Hakky, 2014, Zonal NePhRO scoring system: a superior renal tumor complexity classification model, Clin Genitourin Cancer, 12, e13, 10.1016/j.clgc.2013.07.009 · doi:10.1016/j.clgc.2013.07.009
  13. Albiges, 2024, J Clin Oncol, 42, 4506, 10.1200/JCO.2024.42.16_suppl.4506 · doi:10.1200/jco.2024.42.16_suppl.4506
  14. Giles, 2022, Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: results from a global patient survey in 43 countries, Eur Urol Open Sci, 37, 3, 10.1016/j.euros.2021.12.003 · doi:10.1016/j.euros.2021.12.003
  15. Sprenkle, 2012, Comparison of open and minimally invasive partial nephrectomy for renal tumors 4–7 centimeters, Eur Urol, 61, 593, 10.1016/j.eururo.2011.11.040 · doi:10.1016/j.eururo.2011.11.040
  16. Badalato, 2012, Survival after partial and radical nephrectomy for the treatment of stage T1bN0M0 renal cell carcinoma (RCC) in the USA: a propensity scoring approach, BJU Int, 109, 1457, 10.1111/j.1464-410X.2011.10597.x · doi:10.1111/j.1464-410x.2011.10597.x
  17. Liu, 2021, A meta-analysis for comparison of partial nephrectomy vs. radical nephrectomy in patients with pT3a renal cell carcinoma, Transl Androl Urol, 10, 1170, 10.21037/tau-20-1262 · doi:10.21037/tau-20-1262
  18. Porpiglia, 2021, Transperitoneal vs retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large multi-institutional cohort (the RECORD 2 project), Surg Endosc, 35, 4295, 10.1007/s00464-020-07919-4 · doi:10.1007/s00464-020-07919-4
  19. Gill, 2007, Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors, J Urol, 178, 41, 10.1016/j.juro.2007.03.038 · doi:10.1016/j.juro.2007.03.038
  20. Peyronnet, 2016, Comparison of 1800 robotic and open partial nephrectomies for renal tumors, Ann Surg Oncol, 23, 4277, 10.1245/s10434-016-5411-0 · doi:10.1245/s10434-016-5411-0
  21. Kowalewski, 2024, Randomized controlled feasibility trial of robot-assisted versus conventional open partial nephrectomy: the ROBOCOP II study, Eur Urol Oncol, 7, 91, 10.1016/j.euo.2023.05.011 · doi:10.1016/j.euo.2023.05.011
  22. Cignoli, 2023, Risks and benefits of partial nephrectomy performed with limited or with zero ischaemia time, BJU Int, 132, 283, 10.1111/bju.16009 · doi:10.1111/bju.16009
  23. Sharma, 2023, Off-clamp versus on-clamp robot-assisted partial nephrectomy: a propensity-matched analysis, Eur Urol Oncol, 6, 525, 10.1016/j.euo.2023.04.005 · doi:10.1016/j.euo.2023.04.005
  24. Wood, 2018, Local tumor bed recurrence following partial nephrectomy in patients with small renal masses, J Urol, 199, 393, 10.1016/j.juro.2017.09.072 · doi:10.1016/j.juro.2017.09.072
  25. Bensalah, 2010, Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery, Eur Urol, 57, 466, 10.1016/j.eururo.2009.03.048 · doi:10.1016/j.eururo.2009.03.048
  26. Kim, 2016, Treatment of patients with positive margins after partial nephrectomy, J Urol, 196, 301, 10.1016/j.juro.2016.05.078 · doi:10.1016/j.juro.2016.05.078
  27. Antic, 2015, Partial nephrectomy for renal tumors: lack of correlation between margin status and local recurrence, Am J Clin Pathol, 143, 645, 10.1309/AJCP7LKLZ8JSJQRG · doi:10.1309/ajcp7lklz8jsjqrg
  28. Bekema, 2013, Systematic review of adrenalectomy and lymph node dissection in locally advanced renal cell carcinoma, Eur Urol, 64, 799, 10.1016/j.eururo.2013.04.033 · doi:10.1016/j.eururo.2013.04.033
  29. Capitanio, 2011, Lymph node dissection in renal cell carcinoma, Eur Urol, 60, 1212, 10.1016/j.eururo.2011.09.003 · doi:10.1016/j.eururo.2011.09.003
  30. Gershman, 2018, Radical nephrectomy with or without lymph node dissection for high risk nonmetastatic renal cell carcinoma: a multi-institutional analysis, J Urol, 199, 1143, 10.1016/j.juro.2017.11.114 · doi:10.1016/j.juro.2017.11.114
  31. Tsui, 2000, Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria, J Urol, 163, 1090, 10.1016/S0022-5347(05)67699-9 · doi:10.1016/s0022-5347(05)67699-9
  32. Gershman, 2017, Renal cell carcinoma with isolated lymph node involvement: long-term natural history and predictors of oncologic outcomes following surgical resection, Eur Urol, 72, 300, 10.1016/j.eururo.2016.12.027 · doi:10.1016/j.eururo.2016.12.027
  33. Lardas, 2016, Systematic review of surgical management of nonmetastatic renal cell carcinoma with vena caval thrombus, Eur Urol, 70, 265, 10.1016/j.eururo.2015.11.034 · doi:10.1016/j.eururo.2015.11.034
  34. Kirkali, 2007, A critical analysis of surgery for kidney cancer with vena cava invasion, Eur Urol, 52, 658, 10.1016/j.eururo.2007.05.009 · doi:10.1016/j.eururo.2007.05.009
  35. May, 2009, Pre-operative renal arterial embolisation does not provide survival benefit in patients with radical nephrectomy for renal cell carcinoma, Br J Radiol, 82, 724, 10.1259/bjr/17514226 · doi:10.1259/bjr/17514226
  36. Neves, 2024, Nephron sparing treatment (NEST) for small renal masses: a feasibility cohort-embedded randomised controlled trial comparing percutaneous cryoablation and robot-assisted partial nephrectomy, Eur Urol, 85, 333, 10.1016/j.eururo.2023.07.012 · doi:10.1016/j.eururo.2023.07.012
  37. Prins, 2017, Renal cell carcinoma: alternative nephron-sparing treatment options for small renal masses, a systematic review, J Endourol, 31, 963, 10.1089/end.2017.0382 · doi:10.1089/end.2017.0382
  38. Widdershoven, 2021, Renal biopsies performed before versus during ablation of T1 renal tumors: implications for prevention of overtreatment and follow-up, Abdom Radiol, 46, 373, 10.1007/s00261-020-02613-4 · doi:10.1007/s00261-020-02613-4
  39. Correa, 2019, The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis, Eur Urol Focus, 5, 958, 10.1016/j.euf.2019.06.002 · doi:10.1016/j.euf.2019.06.002
  40. Ali, 2022, The role of stereotactic ablative body radiotherapy in renal cell carcinoma, Eur Urol, 82, 613, 10.1016/j.eururo.2022.06.017 · doi:10.1016/j.eururo.2022.06.017
  41. Tabbara, 2023, Current approaches in surgical and immunotherapy-based management of renal cell carcinoma with tumor thrombus, Biomedicines., 11, 204, 10.3390/biomedicines11010204 · doi:10.3390/biomedicines11010204
  42. Bex, 2022, Efficacy, safety, and biomarker analysis of neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx), J Clin Oncol, 40, 289, 10.1200/JCO.2022.40.6_suppl.289 · doi:10.1200/jco.2022.40.6_suppl.289
  43. Bedke J, Ghanem YA, Albiges L, et al. Updated European Association of Urology guidelines on the use of adjuvant immune checkpoint inhibitors and subsequent therapy for renal cell carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.01.014. · doi:10.1016/j.eururo.2025.01.014
  44. Bex, 2018, Updated European Association of Urology guidelines for cytoreductive nephrectomy in patients with synchronous metastatic clear-cell renal cell carcinoma, Eur Urol, 74, 805, 10.1016/j.eururo.2018.08.008 · doi:10.1016/j.eururo.2018.08.008
  45. Appleman, 2019, Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: a trial of the ECOG-ACRIN cancer research group (E2810), J Clin Oncol, 37, 4502, 10.1200/JCO.2019.37.15_suppl.4502 · doi:10.1200/jco.2019.37.15_suppl.4502
  46. Albiges, 2025, Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): final results of COSMIC-313, J Clin Oncol, 44, 438, 10.1200/JCO.2025.43.5_suppl.438 · doi:10.1200/jco.2025.43.5_suppl.438
  47. Tannir, 2024, Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): long-term follow-up data from the phase 3 CheckMate 214 trial, J Clin Oncol, 42, 363, 10.1200/JCO.2024.42.4_suppl.363 · doi:10.1200/jco.2024.42.4_suppl.363
  48. Beckermann, 2024, Long-term survival in patients with relapsed/refractory advanced renal cell carcinoma treated with tivozanib: analysis of the phase III TIVO-3 trial, Oncologist, 29, 254, 10.1093/oncolo/oyad348 · doi:10.1093/oncolo/oyad348
  49. Ornstein, 2018, Prospective phase II multi-center study of individualized axitinib (Axi) titration for metastatic renal cell carcinoma (mRCC) after treatment with PD-1/PD-L1 inhibitors, J Clin Oncol, 36, 4517, 10.1200/JCO.2018.36.15_suppl.4517 · doi:10.1200/jco.2018.36.15_suppl.4517
  50. Lee, 2023, First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: results of the phase 2 KEYNOTE-B61 study, J Clin Oncol, 41, 4518, 10.1200/JCO.2023.41.16_suppl.4518 · doi:10.1200/jco.2023.41.16_suppl.4518
  51. Lee, 2023, Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: updated results from a phase 2 trial, J Clin Oncol, 41, 4537, 10.1200/JCO.2023.41.16_suppl.4537 · doi:10.1200/jco.2023.41.16_suppl.4537
  52. Bergmann, 2024, LBA75 Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer: results of the SUNNIFORECAST trial, Ann Oncol, 35, S1263, 10.1016/j.annonc.2024.08.2318 · doi:10.1016/j.annonc.2024.08.2318
  53. Przybycin, 2013, Hereditary syndromes with associated renal neoplasia: a practical guide to histologic recognition in renal tumor resection specimens, Adv Anatom Pathol, 20, 245, 10.1097/PAP.0b013e318299b7c6 · doi:10.1097/pap.0b013e318299b7c6
  54. Dabestani, 2019, Increased use of cross-sectional imaging for follow-up does not improve post-recurrence survival of surgically treated initially localized R.C.C.: results from a European multicenter database (R.E.C.U.R.). Scand, J Urol, 53, 14
  55. Capitanio, 2020, Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer, Eur Urol Oncol, 3, 209, 10.1016/j.euo.2019.02.006 · doi:10.1016/j.euo.2019.02.006

Cited by

Metadata

Authors
Bex, A., Ghanem, Y. A., Albiges, L., Bonn, S., Campi, R., Capitanio, U., Dabestani, S., Hora, M., Klatte, T., Kuusk, T., Lund, L., Marconi, L., Palumbo, C., Pignot, G., Powles, T., Schouten, N., Tran, M., Volpe, A., & Bedke, J.
Venue
European Urology
Publisher
Elsevier BV
Published
2025-06
Volume
87
Issue
6
Pages
683-696
ISSN
0302-2838 (ISSN-L)
OpenAlex
W4408674287
Cited by
345
References
77
FWCI
206.58
Type
journal article
Language
en
Open access
hybrid
Licence
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update. https://app.cochat.ai/papers/10.1016/j.eururo.2025.02.020
The paper
Bex, A., Ghanem, Y. A., Albiges, L., Bonn, S., Campi, R., Capitanio, U., Dabestani, S., Hora, M., Klatte, T., Kuusk, T., Lund, L., Marconi, L., Palumbo, C., Pignot, G., Powles, T., Schouten, N., Tran, M., Volpe, A., & Bedke, J. (2025). European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update. European Urology. https://doi.org/10.1016/j.eururo.2025.02.020

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.